CLL
Commentary
Drugs approved in 2013
News
FDA approves ofatumumab for chronic lymphocytic leukemia
News
Persistent lymphocytosis with ibrutinib does not indicate early relapse
Major finding: Patients with chronic lymphocytic leukemia who experienced persistent lymphocytosis associated with ibrutinib treatment did not...
News
Idelalisib and rituximab extends survival in CLL patients
Conference Coverage
ONO-4059 makes waves in heavily pretreated CLL
Major finding: The response rate was 89% overall and 71% for patients with 17p deletion. Data source: A prospective, phase I dose-escalation study...